Generated 2026-06-22 01:15 UTC · ISRG · Research support only, not financial advice
Intuitive Surgical (ISRG): ContraTurtle claim verification, PM pipeline and valuation gate
Review of the “Nvidia of Medtech” article. The core business-quality thesis is well-supported by filings; valuation and several unsourced adoption/ecosystem claims are the weak spots.
Bottom line
PM gateWatchlist / wait
Quality clears; price does not clear margin of safety.
Latest close$406.78
Yahoo chart API, 2026-06-18.
Base DCF~$249
7-year DCF; 9.0% WACC; 3.0% terminal growth.
Verified thesis: dominant installed base, high recurring revenue mix, strong procedure/revenue growth, debt-free balance sheet, and a focused pure-play position in robotic surgery.
Not fully verified: exact market-penetration figures (5% U.S. / 2% Europe / <1% ROW), 76k trained surgeons, and 48k+ peer-reviewed articles were not found in accessible official filings during this run.
Claim verification matrix
| Article claim | Status | Evidence / note |
|---|---|---|
| da Vinci was cleared/launched around 2000 and ISRG is soft-tissue robotic leader. | Verified | ISRG 2025 10-K describes the da Vinci system lineage and current platform. 2025 year-end da Vinci installed base was 11,106 systems. |
| ISRG stock returned roughly +20,000% since 2000 IPO vs S&P about +410%. | Mostly verified | Yahoo monthly chart data: ISRG split-adjusted ~$2.10 in June 2000 to $406.78 on 2026-06-18 = +19,296%. S&P from Jan. 2000 to 2026-06-18 = +438%; exact start date changes result. |
| Robotics accounts for ~95% of U.S. prostatectomies. | Verified | American College of Surgeons Bulletin states approximately 95% of prostatectomies are performed robotically. |
| Robotic surgery is ~5% of all procedures in U.S., 2% Europe, <1% ROW. | Not verified | No accessible primary source located. Filings support “early adoption” broadly but not those exact percentages. |
| I&A is ~60% of revenue and recurring revenue ~84%. | Verified | FY2025 10-K: I&A $6.019B / total revenue $10.065B = 59.8%; recurring revenue $8.465B = 84%. Q1 2026 recurring revenue was 86%. |
| Installed base >11,000 da Vinci systems; >12,000 including Ion. | Verified | FY2025 proxy/10-K: da Vinci 11,106; Ion 995; combined 12,101 systems. |
| 20M+ procedures performed using Intuitive systems. | Plausible | Search indexed an Intuitive press release titled “20 Million Patients Benefit from da Vinci Surgery Globally,” but direct fetch timed out here. Filings verify 3.297M da Vinci+Ion procedures in 2025 alone, making it plausible but not fully fetched. |
| 76,000 surgeons trained and 48,000+ peer-reviewed articles. | Not verified | Not found in accessible 10-K/10-Q/proxy text. Treat as a marketing claim until sourced. |
| da Vinci 5 has broad clearance and Jan. 2026 cardiac expansion. | Verified | ISRG 10-Q: March 2024 FDA clearance for da Vinci 5 for Xi indications except cardiac/pediatric; Jan. 2026 clearance for selected thoracoscopically-assisted cardiac procedures. |
| Medtronic Hugo cleared for U.S. urology; J&J Ottava pending/submitted. | Verified | Medtronic announced Hugo FDA clearance for urologic procedures on 2025-12-03. MedTech Dive reported J&J Ottava de novo submission on 2026-01-07. |
| ISRG debt-free / ~$4.5B net cash. | Verified | Q1 2026 balance sheet: cash & equivalents $2.006B plus short-term investments $2.511B; no debt line item. |
| “Nvidia of Medtech.” | Interpretation | Analogy is supported by ecosystem/installed-base lead, but is not a fact and should not override valuation discipline. |
Broader market / sector context
S&P 500+25.7% 1Y
Nasdaq Composite+36.4% 1Y
10Y Treasury4.45%
IHI med-device ETF-18.6% 1Y
XLV health care ETF+12.7% 1Y
ISRG-20.1% 1Y
Equity tape is broadly risk-on, but medtech has lagged sharply. That is good for hunting quality pullbacks, but a 4.45% 10Y still matters for long-duration growth assets. ISRG has de-rated, yet still trades at a premium multiple.
PM pipeline read
| Lens | Finding | Implication |
|---|---|---|
| Fundamentals | FY2025 revenue $10.065B (+21%); Q1 2026 revenue $2.771B (+23%); FY2025 gross margin 66.0%, op margin 29.3%. | Quality-growth thesis intact. |
| Moat | 11,106 da Vinci systems and high recurring revenue create ecosystem advantage; competitors are real but early. | Moat strong; monitor Hugo/Ottava clearance breadth. |
| Balance sheet | No debt; $4.517B cash + short-term investments at Q1 2026. | Financial risk low. |
| Valuation | Market cap ~$144B; EV/LTM sales ~13.2x; LTM P/E ~48x; FCF yield ~2.0%. | Price requires sustained premium growth and execution. |
| Technical | Price below 50-day (~$440) and 200-day (~$491) moving averages. | No need to chase. |
| PM decision | Business quality clears; valuation does not. | Watchlist; staged-entry only at lower levels. |
Valuation and entry-price framework
| Scenario | Implied value | Assumptions |
|---|---|---|
| Bear DCF | ~$155/share | Revenue growth decays 12%→4%; FCF margin 24.8%; WACC 10.0%; terminal growth 2.5%. |
| Base DCF | ~$249/share | Revenue growth decays 17%→7%; FCF margin 26.8%; WACC 9.0%; terminal growth 3.0%. |
| Bull DCF | ~$361/share | Revenue growth decays 21%→8%; FCF margin 28.8%; WACC 8.5%; terminal growth 3.5%. |
Entry bands (research framework, not trade instruction)
| Band | Price zone | Rationale |
|---|---|---|
| Do not chase | >$380–405 | ~45–48x LTM earnings and above bull DCF. |
| Starter/watchlist | ~$350–360 | Near bull DCF / ~42–43x LTM EPS; still premium. |
| Preferred accumulation | ~$310–330 | ~37–39x LTM EPS; better quality-growth premium. |
| High-conviction valuation | ~$275–295 | ~33–35x LTM EPS and closer to base/bull midpoint. |
| Base DCF zone | ~$250 or lower | Near base DCF; re-underwrite fundamentals first. |
These are non-advisory research levels. Recalculate after Q2/Q3 results and live market data before any portfolio action.
Sources
- ContraTurtle article, 2026-06-20.
- ISRG FY2025 Form 10-K, filed 2026-02-03.
- ISRG Q1 2026 Form 10-Q, filed 2026-04-22.
- ISRG 2026 proxy statement, filed 2026-03-13.
- American College of Surgeons Bulletin, prostatectomy robotics adoption.
- Medtronic Hugo FDA clearance press release, 2025-12-03.
- MedTech Dive on J&J Ottava FDA submission, 2026-01-07.
- Yahoo Finance chart API for prices, index/ETF returns and beta inputs; latest available close 2026-06-18.